Abbott Laboratories
ABT
$133.58
-$0.36-0.27%
NYSE
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 3.95% | 7.16% | 4.85% | 4.00% | 2.23% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 3.95% | 7.16% | 4.85% | 4.00% | 2.23% |
Cost of Revenue | -0.18% | 10.44% | 2.02% | 0.91% | 3.05% |
Gross Profit | 7.31% | 4.58% | 7.20% | 6.52% | 1.57% |
SG&A Expenses | 2.79% | 8.16% | 6.11% | 6.83% | 7.00% |
Depreciation & Amortization | -11.02% | -3.33% | -5.24% | -5.42% | -3.87% |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 0.45% | 10.35% | 3.19% | 1.79% | 4.04% |
Operating Income | 23.45% | -4.90% | 12.72% | 14.91% | -6.81% |
Income Before Tax | 23.82% | 13.09% | 16.10% | -1.77% | -8.07% |
Income Tax Expenses | 114.69% | -3,681.59% | 25.11% | 16.86% | -13.52% |
Earnings from Continuing Operations | 8.16% | 478.98% | 14.62% | -5.31% | -7.06% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 8.16% | 478.98% | 14.62% | -5.31% | -7.06% |
EBIT | 23.45% | -4.90% | 12.72% | 14.91% | -6.81% |
EBITDA | 13.22% | -3.75% | 7.79% | 10.29% | -4.60% |
EPS Basic | 8.23% | 479.67% | 14.56% | -5.40% | -6.98% |
Normalized Basic EPS | 26.27% | -6.92% | 16.05% | 11.86% | -7.99% |
EPS Diluted | 8.57% | 479.43% | 14.63% | -5.40% | -6.67% |
Normalized Diluted EPS | 26.35% | -6.92% | 16.14% | 11.86% | -7.95% |
Average Basic Shares Outstanding | -0.06% | -0.11% | 0.04% | 0.06% | -0.09% |
Average Diluted Shares Outstanding | -0.14% | -0.11% | -0.04% | 0.06% | -0.12% |
Dividend Per Share | 7.27% | 7.27% | 7.84% | 7.84% | 7.84% |
Payout Ratio | -0.01% | -0.81% | -0.06% | 0.14% | 0.16% |